Risk-Adapted Adjuvant Chemo After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for People Along with Resectable CT3-4 or even N+ Arschfick Cancers: Five-Year Disease-Free Emergency Outcomes of a Single-Center Sequence.